RxDoctor Payments Data

Vikas Patel, MD

Cardiovascular Disease · Kankakee, ILNPI 1235349598

Payments from drug & device makers

$55,768in general payments, 2019–2025

Across 698 payments — averaging $79.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$17K
  • Medtronic$9K
  • Bard Peripheral Vascular, Inc.$6K
  • Cardiovascular Systems Inc.$5K
  • Philips North America LLC$4K
  • Novartis$2K
  • plus $12K from 52 others

What the payments were for

  • Consulting fees$5,48511%
  • Speaking & faculty fees$20,20041%
  • Grants$660%
  • Travel & lodging$6,86514%
  • Food & beverage$16,32233%
  • Education$1600%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,768 in reported general payments places this provider in the 85th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$432,887
Medicare patients
1,927
Services billed
5,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban478$560,420
XareltoRivaroxaban215$250,534
EntrestoSacubitril/Valsartan124$182,840
Repatha SureclickEvolocumab89$99,722
JardianceEmpagliflozin62$84,302
FarxigaDapagliflozin Propanediol70$73,274
BrilintaTicagrelor38$24,067
Atorvastatin Calcium969$11,087
Metoprolol Succinate753$10,779
DapagliflozinDapagliflozin Propanediol11$10,494
ClopidogrelClopidogrel Bisulfate510$6,657
Ezetimibe198$6,308
Rosuvastatin Calcium463$5,842
Losartan Potassium389$4,774
Lisinopril373$3,916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$539$560,420478 claims
Johnson & JohnsonXarelto$982$250,534215 claims
NovartisEntresto$2,335$182,840124 claims
AstraZenecaFarxiga, Brilinta$368$97,341108 claims
Boehringer IngelheimJardiance$421$84,30262 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Kankakee

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →